The primary patent for Xarelto (rivaroxaban) is set to expire in November 2026 [1]. This expiration refers to the U.S. Patent No. 7,279,466, which covers the composition of matter for rivaroxaban [2].
When does other Xarelto exclusivity expire?
Beyond the composition of matter patent, other forms of exclusivity may influence market entry for generic versions. For instance, Orange Book listings indicate that the patent for rivaroxaban's method of use, specifically for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, is also set to expire around the same time as the primary patent [1].
What happens when the Xarelto patent expires?
Upon the expiration of the primary patents and any associated exclusivities, generic manufacturers may seek to market their own versions of rivaroxaban. This typically leads to increased competition, which often results in lower drug prices for consumers and healthcare systems [3]. The process involves Abbreviated New Drug Applications (ANDAs) filed with the U.S. Food and Drug Administration (FDA), which rely on the innovator drug's data to demonstrate bioequivalence [4].
Are there any pending challenges to Xarelto patents?
Patent challenges can occur before the official expiration date. These challenges, often brought by generic manufacturers, aim to invalidate or circumvent existing patents, potentially paving the way for earlier market entry for generics. Information on specific patent challenges for Xarelto can be found on resources like DrugPatentWatch.com [1].
Who makes Xarelto and who are its competitors?
Xarelto is manufactured by Bayer Pharmaceuticals. It is a direct oral anticoagulant (DOAC) and competes with other DOACs such as Eliquis (apixaban) made by Bristol Myers Squibb and Pfizer, and Pradaxa (dabigatran etexilate) made by Boehringer Ingelheim [5][6].
What is the mechanism of action for Xarelto?
Xarelto's active ingredient, rivaroxaban, is a direct Factor Xa inhibitor. By inhibiting Factor Xa, it blocks a key step in the coagulation cascade, thereby preventing the formation of thrombin and the subsequent development of blood clots [2].
What are the risks and side effects associated with Xarelto?
The primary risk associated with Xarelto, like other anticoagulants, is bleeding. Patients taking Xarelto are advised to seek immediate medical attention if they experience signs of serious bleeding, such as unusual bruising, prolonged bleeding from cuts, nosebleeds, bleeding gums, increased menstrual or vaginal bleeding, blood in urine or stools, or coughing up blood [7]. Other potential side effects may include dizziness, fatigue, and abdominal pain [7].
How does Xarelto compare to other anticoagulants?
Xarelto is a direct oral anticoagulant (DOAC), a class of drugs that has largely replaced warfarin (a vitamin K antagonist) for many indications due to advantages like predictable dosing without the need for regular blood monitoring and fewer food and drug interactions [5]. Compared to other DOACs like Eliquis and Pradaxa, Xarelto has demonstrated comparable efficacy and safety profiles in various clinical trials for conditions like stroke prevention in atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism [5][6].
What is the clinical data supporting Xarelto's use?
Key clinical trials for Xarelto include ROCKET AF, which demonstrated its non-inferiority to warfarin in preventing stroke in patients with atrial fibrillation [5]. The EINSTEIN program trials provided evidence for its efficacy in treating and preventing deep vein thrombosis and pulmonary embolism [5].
What is the cost of Xarelto and potential generic pricing?
The cost of Xarelto can vary significantly based on insurance coverage, dosage, and pharmacy. Historically, brand-name drugs are considerably more expensive than their generic counterparts. Following patent expiration and the introduction of generic rivaroxaban, prices are expected to decrease substantially [3].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202251s026lbl.pdf
[3] https://www.hhs.gov/about/agencies/negotiation/drug-pricing/generic-drugs/index.html
[4] https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas-generic-drugs/what-abbreviated-new-drug-application-anda
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa1009632
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110035/
[7] https://www.xarelto-us.com/patient/about-xarelto/safety-information